{"entity":{"id":"nct07162883","kind":"trial","name":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","aka":[],"tldr":"A phase 3 trial of QL2107 and pembrolizumab in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.","summary":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) is a phase 3, randomised interventional study registered as NCT07162883 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 122 participants, started 2025-09-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: QL2107; Keytruda®. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: AUCtau,sd of QL2107 and Keytruda; AUCtau,ss of QL2107 and Keytruda. Lung eligibility wording from the registry: \"* Disease status: Participants with completely resected, histologically- or cytologically-confirmed (Stage II or IIIA) NSCLC\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07162883","url":"https://clinicaltrials.gov/study/NCT07162883"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["ql2107","pembrolizumab"],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07162883","phase":"3","setting":"A Randomized, Double-Blind, Multicenter, Pharmacokinetic Equivalence Clinical Trial of QL2107 (Keytruda® Biosimilar Candidate) in Comparison With Keytruda® (Pembrolizumab) for Adjuvant Therapy to Demonstrate Pharmacokinetic Similarity in Subjects With Resected Non-Small Cell Lung Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","enrolled":122,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07162883/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"ql2107","kind":"drug","name":"QL2107","route":"/drugs/ql2107/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}